Tag Archive for: antibody drug conjugates

Adcendo ApS Announces License Agreement with Duality Biologics on Next-generation ADC Platform

/in

Adcendo licenses Duality’s DITAC (Duality Immune Toxin Antibody Conjugates) linker/payload platform for its lead uPARAP-ADC program Agreement based on synergies between Adcendo and Duality in generating breakthrough ADCs in hard-to-treat cancers Copenhagen, Denmark, January 5, 2023 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of […]

Read more

Synaffix Named ‘Biotech Company of the Year’ at the LSX European Lifestars Awards

/in

AMSTERDAM, THE NETHERLANDS, November 16, 2022 – Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces the Company has been awarded ‘Biotech Company of the Year 2022’ at the annual LSX, European Lifestars Awards Ceremony, held on the 14th of November at […]

Read more